Trial
NCT04369469
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
COVID-19 Severe Pneumonia
Intervention
Ravulizumab
Why stopped
Met futility bar at interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-24